Evaluation of Sulfasalazine as an Adjunctive Therapy in Treating Pulmonary Pre-XDR-TB: Efficacy, Safety, and Treatment Implication.

Liang FuWenfei WangJuan Xiong Peize Zhang Hui LiXilin ZhangHancheng LiangQianting YangZhaoqin WangXinchun ChenGuofang DengYi CaiShenjie Tang

Published in: Infection and drug resistance (2024)

Both 9-month short-course, all-oral regimens manifested commendable primary efficacy in treating pre-XDR-TB patients. The SASP-regimen emerged as effective, safe, well-tolerated, and cost-effective.

Keyphrases

drug resistant
mycobacterium tuberculosis
end stage renal disease
newly diagnosed
ejection fraction
pulmonary hypertension
prognostic factors
patient reported outcomes
bone marrow
multidrug resistant
patient reported